The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Yasui, Hironobu ^a   Asanuma, Taketoshi ^b   Kino, Junichi ^a   Yamamori, Tohru ^a   Meike, Shunsuke ^a   Nagane, Masaki ^a   Kubota, Nobuo ^c   Kuwabara, Mikinori ^a   Inanami, Osamu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c POLA PHARMA INC   (Japan)

Author keywords

Doranidazole; Glioblastoma; Hypoxia; Radiosensitizer

Indexed keywords

DORANIDAZOLE; RADIOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; CELL DEATH; CLONOGENIC ASSAY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG MECHANISM; ELECTRON SPIN RESONANCE; GLIOBLASTOMA; HYDROPHILICITY; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR GROWTH; X IRRADIATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; IMIDAZOLES; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RATS;

EID: 84874752632     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-106     Document Type: Article

References (33)

1. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000, 1(5):459-468. 10.1007/s11864-000-0073-2, 12057153.
2. Forsyth PA, Cairncross JG. Treatment of malignant glioma in adults. Curr Opin Neurol 1995, 8(6):414-418. 10.1097/00019052-199512000-00002, 8845922.
3. Robins HI, Chang S, Butowski N, Mehta M. Therapeutic advances for glioblastoma multiforme: current status and future prospects. Curr Oncol Rep 2007, 9(1):66-70. 10.1007/BF02951428, 17164050.
4. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009, 92(3):317-335. 10.1007/s11060-009-9827-2, 19357959.
5. Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 2004, 58(3):927-931. 10.1016/j.ijrobp.2003.09.092, 14967452.
6. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8(7):545-554.
7. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4(6):437-447. 10.1038/nrc1367, 15170446.
8. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009, 172(6):653-665. 10.1667/RR1926.1, 2790140, 19929412.
9. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003, 138(8):659-668.
10. Nagasawa H, Uto Y, Kirk KL, Hori H. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull 2006, 29(12):2335-2342. 10.1248/bpb.29.2335, 17142959.
11. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25(26):4066-4074. 10.1200/JCO.2007.12.7878, 17827455.
12. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 2004, 14(3):233-240. 10.1016/j.semradonc.2004.04.002, 15254866.
13. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989, 16(4):1065-1068. 10.1016/0360-3016(89)90917-6, 2649462.
14. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46(2):135-146. 10.1016/S0167-8140(97)00220-X, 9510041.
15. Oya N, Shibamoto Y, Sasai K, Shibata T, Murata R, Takagi T, Iwai H, Suzuki T, Abe M. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol Phys 1995, 33(1):119-127. 10.1016/0360-3016(95)00040-6, 7642409.
16. Kuwabara M, Iida Y, Inanami O, Sawamura S, Yokoyama K, Tsujitani M. Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350). J Radiat Res (Tokyo) 2002, 43(1):77-88.
17. Aoki M, Furusawa Y, Shibamoto Y, Kobayashi A, Tsujitani M. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells. J Radiat Res (Tokyo) 2002, 43(2):161-166.
18. Hamasu T, Inanami O, Tsujitani M, Yokoyama K, Takahashi E, Kashiwakura I, Kuwabara M. Post-irradiation hypoxic incubation of X-irradiated MOLT-4 cells reduces apoptotic cell death by changing the intracellular redox state and modulating SAPK/JNK pathways. Apoptosis 2005, 10(3):557-567. 10.1007/s10495-005-1888-x, 15909118.
19. Shibamoto Y, Kubota T, Kishii K, Tsujitani M. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol 2000, 56(2):265-270. 10.1016/S0167-8140(00)00181-X, 10927148.
20. Murata R, Tsujitani M, Horsman MR. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother Oncol 2008, 87(3):331-338. 10.1016/j.radonc.2008.03.002, 18375007.
21. Yahiro T, Masui S, Kubota N, Yamada K, Kobayashi A, Kishii K. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J Radiat Res (Tokyo) 2005, 46(3):363-372.
22. Sunamura M, Karasawa K, Okamoto A, Ogata Y, Nemoto K, Hosotani R, Nishimura Y, Matsui K, Matsuno S. Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas 2004, 28(3):330-334. 10.1097/00006676-200404000-00023, 15084982.
23. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 2007, 13(6):1663-1674. 10.1158/1078-0432.CCR-06-2854, 17363519.
24. Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, Paulus W. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 2004, 107(3):272-276. 10.1007/s00401-003-0810-2, 14730455.
25. Towner RA, Smith N, Doblas S, Garteiser P, Watanabe Y, He T, Saunders D, Herlea O, Silasi-Mansat R, Lupu F. In vivo detection of inducible nitric oxide synthase in rodent gliomas. Free Radic Biol Med 2010, 48(5):691-703. 10.1016/j.freeradbiomed.2009.12.012, 20034558.
26. Asanuma T, Doblas S, Tesiram YA, Saunders D, Cranford R, Yasui H, Inanami O, Smith N, Floyd RA, Kotake Y. Visualization of the protective ability of a free radical trapping compound against rat C6 and F98 gliomas with diffusion tensor fiber tractography. J Magn Reson Imaging 2008, 28(3):574-587. 10.1002/jmri.21474, 18777527.
27. Liu R, Wen Y, Perez E, Wang X, Day AL, Simpkins JW, Yang SH. 17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. Brain Res 2005, 1060(1-2):55-61.
28. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009, 8(4):947-958. 10.1158/1535-7163.MCT-08-0981, 2908257, 19372568.
29. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000, 20(2):217-230. 10.1023/A:1007049806660, 10696511.
30. Weinmann M, Welz S, Bamberg M. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology. Curr Med Chem Anticancer Agents 2003, 3(5):364-374. 10.2174/1568011033482350, 12871083.
31. Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 2005, 23(8):833-841. 10.1016/j.mri.2005.06.007, 16275421.
32. Matsumoto S, Yasui H, Batra S, Kinoshita Y, Bernardo M, Munasinghe JP, Utsumi H, Choudhuri R, Devasahayam N, Subramanian S. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc Natl Acad Sci USA 2009, 106(42):17898-17903. 10.1073/pnas.0908447106, 2761243, 19815528.
33. Yasui H, Matsumoto S, Devasahayam N, Munasinghe JP, Choudhuri R, Saito K, Subramanian S, Mitchell JB, Krishna MC. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res 2010, 70(16):6427-6436. 10.1158/0008-5472.CAN-10-1350, 2922437, 20647318.